GlassScriptPhysician profile
Carlos Jacinto
NPI 1356336739
$1,833.34
in general payments reported to CMS, 2019-2025
15 companies · $68.08 in 2025
The $68.08 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $112 · 2021: $213 · 2022: $71.19 · 2023: $254 · 2024: $434 · 2025: $68.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743 · Education: $13.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.74 |
| Education | $13.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $464.71 | 2019-2024 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $273.80 | 2019-2024 | Fasenra, Airsupra |
| Pfizer INC. | $189.52 | 2019-2024 | |
| Genentech USA, INC. | $187.65 | 2023-2024 | Xolair |
| Optinose US, INC. | $118.24 | 2019-2021 | |
| Genzyme Corporation | $117.30 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $100.25 | 2019-2020 | |
| Csl Behring | $89.88 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $88.50 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.07 | 2022-2024 | Takhzyro |
| Octapharma USA, INC. | $48.67 | 2019-2020 | |
| Edwards Lifesciences Corporation | $21.30 | 2024 | |
| Kaleo, INC. | $20.20 | 2019 | |
| Biocryst US Sales Co., LLC | $20.10 | 2023 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $19.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Jacinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.